It is important to emphasize that the BCMA positivity of some myeloma subclones can be radically reduced spontaneously or as a possible result of long-term drug treatment, which can be a resistance mechanism against BCMA-targeted therapies. Here, TNFRSF17 is linked to plasma cell myeloma.